Ursodeoxycholic Acid interactions

Full monograph for Ursodeoxycholic Acid Check it against another medicine

Medicines

387 documented

Severity

Medicines documented to interact with Ursodeoxycholic Acid, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Aluminium Hydroxide + Magnesium Hydroxide	Minor	Absorption	Aluminum-containing antacids may reduce the absorption of ursodiol. The clinical significance is unknown. Monitoring for altered efficacy may be advisable.	1 sources — open the full entry
Aluminium Hydroxide + Magnesium Hydroxide + Simethicone	Minor	Absorption	Aluminum-containing antacids may reduce the absorption of ursodiol. The clinical significance is unknown. Monitoring for altered efficacy may be advisable.	1 sources — open the full entry
Cyclosporine (Oral)	Minor	Absorption	Bile acid salts may increase the bioavailability of oral cyclosporine. Data have been conflicting. The mechanism and clinical significance are unknown. No…	14 sources — open the full entry
Magaldrate	Minor	Absorption	Aluminum-containing antacids may reduce the absorption of ursodiol. The clinical significance is unknown. Monitoring for altered efficacy may be advisable.	1 sources — open the full entry
Magaldrate + Simethicone	Minor	Absorption	Aluminum-containing antacids may reduce the absorption of ursodiol. The clinical significance is unknown. Monitoring for altered efficacy may be advisable.	1 sources — open the full entry

Conditions

Conditions in which Ursodeoxycholic Acid needs care, as documented in this source.

Cholestasis
Major
The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.
2 sources
1. "Product Information. Actigall (ursodiol)." Novartis Pharmaceuticals (2022):
2. "Product Information. Urso (ursodiol)." Scandipharm Inc (2001):
Hepatic Insufficiency
Moderate
Ursodiol therapy has not been associated with liver damage. However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate. Close monitoring should be exercised in patients with liver impairment. Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.
2 sources
1. "Product Information. Actigall (ursodiol)." Novartis Pharmaceuticals (2022):
2. "Product Information. Urso (ursodiol)." Scandipharm Inc (2001):